Atlas Trials

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Clinical trial NCT05025800 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05025800
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Aggressive B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaComposite LymphomaIndolent B-Cell Non-Hodgkin LymphomaRefractory Aggressive B-Cell Non-Hodgkin LymphomaRefractory Follicular Lymphoma
Start date
2021-10-13
Primary completion
2028-03-21
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.